Genmab to Hold ASH 2016 Data Review Meeting Media Release

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Genmab to Hold ASH 2016 Data Review Meeting

Media Release

  • Key Opinion Leaders to discuss daratumumab data presented at the 2016 ASH meeting
  • Meeting to be webcast live and archived on www.genmab.com 

Copenhagen, Denmark; December 1, 2016 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold an ASH 2016 Data Review Meeting on December 5, 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 6 December).  The event will include presentations by key opinion leaders on data from studies of daratumumab presented at the 58th Annual Meeting of the American Society of Hematology (ASH).

The following cancer experts and senior Genmab staff will speak at the event:  

Key Opinion Leaders:

  • Dr. Meletios-Athanasios Dimopoulos, National and Kapodistrian University of Athens, School of Medicine
  • Prof. Philippe Moreau, University Hospital of Nantes
  • Dr. Saad Usmani, University of North Carolina at Chapel Hill, Levine Cancer Institute

Genmab:

  • Dr. Jan van de Winkel, President and CEO, Genmab
  • David Eatwell, Executive Vice President and CFO, Genmab

The Data Review Meeting will take place at the Manchester Grand Hyatt in San Diego, California, Harbor Ballroom A. Those wishing to attend in person should email c.hahner@genmab.com

The event can also be attended via webcast. To view this webcast visit: http://edge.media-server.com/m/p/fatt4nhn .   Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX ® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra ® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications, non-Hodgkin’s lymphoma and solid tumors.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody ® platform for generation of bispecific antibodies, and the HexaBody ® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .   

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements in relation to actual results, unless required by law. Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

Media Release no. 14 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LiberNovo's Black Friday Chair Sale Tests Premium Demand

Updated Category News Views 81

Ergonomic chairs are not impulse purchases, and LiberNovo knows it. Its Black Friday push in the United States and Canada runs through November 30, throwing discounts, gifts, prize-wheel entries and loyalty points at buyers considering a fairly expensive piece of office equipment. That is a lot of promotional machinery for a chair sale, but the underlying pitch is...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 70

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
First US Extends Buyback Clock Through Year-End 2027

Updated Category News Views 199

A buyback extension is not a thunderclap; it is a bank board keeping a useful tool within reach. First US Bancshares has pushed the expiration of its existing repurchase authorization from December 31, 2026, to December 31, 2027. That matters, but investors ought to resist turning a calendar change into a grand earnings prophecy. The company has bought back 2,122,972...

Continue Reading
Rare Stellar Merger Validates RIT Theory in Nature

Updated Category News Views 82

One star swallowed another’s orbit, and astronomy finally caught the evidence. That is the plain-English punch of the observation called AT 2025abao in the Andromeda Galaxy, and it is a meaningful one for Jason Nordhaus and his colleagues at Rochester Institute of Technology. On Nov. 18, research published in Nature validated a scenario Nordhaus’s team had predicted...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
LiberNovo's European Black Friday Sale Tests Demand

Updated Category News Views 139

A €1,339 chair has no business pretending it is an impulse buy, which is exactly why LiberNovo’s Black Friday push deserves a closer look. The Hong Kong-based ergonomic-chair seller has rolled out its Black Friday sale across the European Union and United Kingdom, with the campaign ending November 30 at 23:59 CET in the EU and 23:59 GMT in the UK. This is a...

Continue Reading
Sinopec's Green Fuel Push Meets a Hard Reality Check

Updated Category News Views 150

A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....

Continue Reading
Aimbient's OR Timestamp Study Puts Efficiency to Test

Updated Category News Views 160

A camera catching a patient’s arrival on time may sound mundane, but operating rooms are where mundane details can turn into serious money and better operational decisions. Aimbient’s newly corrected announcement points to an independently conducted Stanford Medicine study in JAMA Surgery that tested whether its computer-vision system could document key operating-room...

Continue Reading
Thanksgiving AI Talk Needs Better Safety Questions

Updated Category News Views 108

Thanksgiving has somehow acquired a new household hazard: somebody casually pasting private information into a chatbot between football and dessert. SBS CyberSecurity’s point is sensible, and it lands because this is no longer a niche tech habit. Pew Research Center says 49% of U.S. adults use AI chatbots, up from roughly one-third in 2024. That kind of adoption curve...

Continue Reading
Goosehead Restatement Puts Accounting Trust on Trial

Updated Category News Views 87

A filing delay can be irritating; a multi-year no-rely warning is something uglier. Goosehead Insurance told investors on November 9, 2026, that it would not timely file its quarterly report for the period ended September 30 and that prior financial statements must be restated. That is not a garden-variety paperwork hiccup. It reaches back across fiscal 2023, 2024 and...

Continue Reading

Top 5 Most Recently Viewed Articles

Pacific Valley Bancorp Delivers Financial Performance Insights

Updated Category News Views 246

Financial Overview of Pacific Valley Bancorp Pacific Valley Bancorp, a holding company for Pacific Valley Bank, has shared its third-quarter financial results, indicating noteworthy trends and developments in its financial landscape. The bank reported a net income of $950 thousand for the quarter, reflecting a 16.5% decrease from the previous year's performance largely...

Continue Reading
KULR Enhances AI Data Center Energy Solutions with OCP Membership

Updated Category News Views 176

KULR Technology Group Joins Open Compute Project as Platinum Member KULR Technology Group, Inc. (NYSE American: KULR) is making significant strides in the energy storage landscape by joining the Open Compute Project (OCP) as a Platinum Member. This partnership comes at a time when the demand for innovative energy solutions in AI data centers is surging. KULR, known for...

Continue Reading
Investors of XPLR Infrastructure, LP Could Join Class Action

Updated Category News Views 90

Investors Encouraged to Join Class Action Against XPLR Infrastructure Levi & Korsinsky, LLP is reaching out to investors of XPLR Infrastructure, LP, formerly known as Nextera Energy Partners, LP, to inform them about a class action securities lawsuit. The company, identified by the ticker symbol XIFR, is currently facing allegations of securities fraud that potentially...

Continue Reading
Understanding Teck Resources' Recent Options Movements

Updated Category News Views 151

Investors Keeping a Close Eye on Teck Resources Recently, it has been observed that financial investors have adopted a bullish outlook regarding Teck Resources (TECK). This perspective is important for both seasoned and retail traders in the market. The activity on Teck’s options historically gives valuable insights, particularly in dynamic trading environments....

Continue Reading
Understanding the Class Action Lawsuit Against Lineage, Inc.

Updated Category News Views 201

Overview of Class Action Lawsuit Lineage, Inc. (NASDAQ: LINE) is currently facing a class action lawsuit that has garnered significant attention from shareholders and the legal community alike. This lawsuit represents individuals who purchased shares of Lineage's common stock during a specific class period linked to the company's registration statement from its initial...

Continue Reading